DOCSLIB.ORG

Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table of contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in M&A dealmaking 2.1. Introduction 2.2. Difference between merger and acquisition deals 2.3. Trends in M&A deals since 2009 2.3.1. Japanese M&A accelerates 2.3.2. Option to acquire the new acquisition? 2.3.3. Case study 1: Cephalon – Ception 2.3.4. Case study 2: HertArt Aps – Vitrolife 2.4. When M&A can be useful 2.5. Attributes of M&A deals 2.5.1. M&A as an alternative to IPO 2.6. Partnering deals with M&A component 2.6.1. Partnering as a precursor to M&A 2.6.1.a. Case study 3: Celgene – VentiRx Pharmaceuticals, Oct 2012 2.6.2. Equity as part of partnering deal 2.6.2.a. Case study 4: BioMarin – Catalyst Pharma Partners, Oct 2012 2.6.2.b. Case study 5: Pfizer – Clovis Oncology , June 2011 2.6.2.c. Case study 6: Tesaro – OPKO Health, December 2010 2.6.3. Conversion of partnership to acquisition 2.6.4. But M&A is not always the route followed 2.7. Big pharma mega mergers – are we at the end of the road? 2.7.1. Growth of Johnson & Johnson through M&A 2.7.2. Growth of Novartis through M&A 2.8. Accessing innovation through M&A 2.8.1. Big pharma acquisitions of small companies 2.8.1.a. Case study 7: Abbott – Facet Biotechnology 2.8.1.b. Case study 8: Gilead Sceinces – Pharmasset 2.8.2. Medium and small biopharma – use of M&A 2.8.2.a. Case study 9: Allergan – MAP Pharmaceuticals 2.8.2.b. Case study 10: Reckitt Benckiser – Schiff Nutrition International 2.8.3. Using M&A to build a company 2.8.3.a. Case study 11: Shire – built from M&A 2.8.3.b. Case study 12: Zeneus - acquiring a ready-made European capability 2.8.3.c. Case study 13: Novartis – from pure pharma to half generic 2.8.4. Emergence of biotech-biotech mergers 2.8.4.a. Case study 14: Merger between Biogen and Idec 2.8.4.b. Case study 15: Amgen acquisition activity 2.9. The emerging role of private equity in M&A 2.10. Implementing M&A transactions 2.11. Joint ventures as alternative to M&A 2.12. The future of M&A in biopharma Chapter 3 – Overview of M&A deal structure 3.1. Introduction 3.2. Pure versus multi-component acquisition deals 3.3. Pure M&A agreement structure 3.3.1. Example acquisition agreements 3.3.1.a. Case study 16: Allergan - SkinMedica – November 2012 3.4. Acquisition as part of a wider alliance agreement 3.4.1. Example acquisition option clauses 3.4.1.a. Case study 17: MGI Pharma – AkaRx – October 2007 3.5. Merger agreements 3.5.1. Example merger agreements 3.5.1.a. Case study 18: Synergy Pharmaceuticals – Callisto Pharmaceuticals – July 2012 Chapter 4 – Leading M&A deals 4.1. Introduction 4.2. Top M&A deals by value 4.3. Top merger deals 4.4. Most active M&A dealmakers 4.5. Big pharma M&A deal activity 4.6. Big biotech M&A deal activity Chapter 5 – Big pharma M&A deals 5.1. Introduction 5.2. How to use M&A deals 5.3. Big pharma company M&A deal profiles Abbott Abbvie Actavis Allergan Amgen Aspen Pharmacare Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Endo Pharmaceuticals Forest Laboratories Fresenius Gilead Sciences GlaxoSmithKline Grifols Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Merck & Co Merck KGaA Mitsubishi Tanabe Mylan Novartis Otsuka Pfizer Roche Sanofi Servier Shionogi Shire Sun Pharmaceutical Takeda Teva UCB Valeant Chapter 6 – Big biotech M&A deals 6.1. Introduction 6.2. How to use M&A deals 6.3. Big biotech company M&A deal profiles 3SBio Acorda Therapeutics Actelion Alexion Pharmaceuticals Alkermes AMAG Pharmaceuticals Anika Therapeutics Bavarian Nordic Biocon BioMarin Pharmaceuticals Cangene Celgene Cubist Elan Emergent BioSolutions Enzo Biochem Galapagos Ipsen Isis Pharmaceuticals LFB Group Morphosys Onyx Pharmaceuticals Optimer Questcor Pharmaceuticals SciClone Pharmaceuticals Spectrum Pharmaceuticals Swedish Orphan Biovitrum The Medicines Company United Therapeutics Vertex Pharmaceuticals ViroPharma Chapter 7 – M&A contracts directory 7.1. Introduction 7.2. Company A-Z Abbott Laboratories Abbvie Abraxis BioScience Abraxis Health Accelerated Care Plus AccelPath Accelrys Accuray Acon Labs Acorda Therapeutics Actavis Actavis (acquired by Watson) Actinium Pharmaceuticals Adamis Pharmaceuticals Adeona Pharmaceuticals Adolor Advanced Biohealing Advanced Medical Optics Adventrx Pharmaceuticals Aetna AGA Medical Agila Specialties Agilent Technologies Akorn Albany Molecular Research Aldagen Alexion Pharmaceuticals Alexza Pharmaceuticals Alkermes Allergan Allezoe Medical Allos Therapeutics Allozyne Alpha Innotech Alphatec Spine Alpine Biomed Amag Pharmaceuticals Amarin American Medical Systems Amerifit Brands Amgen Amorcyte Amsterdam Molecular Therapeutics Amylin Pharmaceuticals Anchen Pharmaceuticals Anesiva ANI Pharmaceuticals Anika Therapeutics AorTx Apax Partners Applied Genomics Aptalis Pharma Apthera AquaMed Technologies Arcion Therapeutics Ardea Biosciences Arigene Ariston Pharmaceuticals Arrayit Diagnostics Arresto BioSciences Arrow Group Arthrocare Asahi Kasei Ashland Aspect Medical Systems Assay Designs AssuraMed Astellas Pharma Astex Pharmaceuticals Astex Therapeutics Astra Tech AstraZeneca Atlas Acquisition Corp ATS Medical Aurora Diagnostics Avalon Pharmaceuticals AVANYX Therapeutics Avista Capital Partners AxoGen Azur Pharma Banner Health Bausch & Lomb Baxter International Bayer Healthcare BBC Graphics Beckman Coulter Beijing Genomics Institute (BGI) Belgian Volition Bio-Imaging Technologies BioClinica Biocompatibles International BioCryst Pharmaceuticals Bioform Medical BioMarin Pharmaceutical BioMimetic Therapeutics Bioniche Pharma BioReliance BioSante Pharmaceuticals BioScrip BioSphere Medical Biotel BioTelemetry BioTime Biovail BioVectra Biovex Blackstone Lake Minerals Bohai Pharmaceuticals Group Boston Therapeutics Bristol-Myers Squibb BTG Byrne Medical Cactus Ventures Cadence Pharmaceuticals Cahaba Pharmaceuticals Caleco Pharma California Stem Cell Caliper Life Sciences Calistoga Pharmaceuticals Calixa Therapeutics Callisto Pharmaceuticals Cambrex Cambrex Zenara Cambridge Research and Instrumentation Canada Pension Plan Investment Board Candela Cantel Medical Cape Cod Cardiac Cath Cape Cod Cardiology Services Cape Cod Hospital Caraco Pharmaceuticals Cardiac Science Cardinal Health CardioCORE Lab Cardiogenesis Cardiokine Cardo Medical CareDx Celera Celgene Cell Biosciences Cell Genesys Cell Therapeutics Celldex Therapeutics Cellectar Biosciences Cephalon Ception Therapeutics Cequent Pharmaceuticals Cesca Therapeutics Charles River Laboratories Charterhouse Equity Partners Chief Respect Chiesi Farmaceutici China Biopharmaceuticals China Medicine Corporation China PharmaHub CitySync Clarient Claros Diagnostics Clinical Data CNS Wellness CombinatoRx Commonwealth Biotechnologies Complete Genomics Conceptus Conmed Cornerstone Therapeutics Cortex Pharmaceuticals Cougar Biotechnology Covella Pharmaceuticals Coventry Health Care Covidien CPEX Pharmaceuticals Crealta Pharmaceuticals Critical Homecare Solutions Crucell Cryolife Cubist Pharmaceuticals Curacyte Discovery Curagen Curaxis Pharmaceuticals CV Therapeutics CyDex Cypress Pharmaceutical Cyrenaic Pharmaceuticals Cytomedix Cytopia Dainippon Sumitomo Pharma Dako Danaher Dentsply International Denville Scientific Derma Sciences Dermik Laboratories Diagnostic Hybrids Dialysis Corp of America DigiPath Solutions Dionex Divine Skin Laboratories Dragon Pharmaceutical DS Healthcare DSM DUSA Pharmaceuticals Dynavax Technologies EKR Therapeutics Elan Elan Drug Technologies Eli Lilly Emergent BioSolutions Endo Pharmaceuticals Endologix Enobia Pharma Enzo Biochem Eon Labs EpiCept EQT Ester Neurosciences Etrials Worldwide EUSA Pharma Ev3 Excelsyn Express Scripts Facet Biotechnology FasTrack Pharmaceuticals Fero Industries Fidia Advanced Biopolymers Fidia Farmaceutici FluoroPharma Medical Footstar Forest Laboratories Forest Pharmaceuticals Fujifilm GE Healthcare Gemin X Pharmaceuticals Gen-Probe Genentech Generex Biotechnology GeneSeek GenturaDx Genzyme Gilead Sciences GL Biochem GlaxoSmithKline Global Med Technologies Global Medical Direct Glycosan BioSystems Grifols GTC Biotherapeutics Guangzhou LifeTech Pharmaceuticals Haemonetics Corporation Hanger Orthopedic Group Hansen Medical Hartlab Harvard Bioscience Hasco Medical HealthTronics Heart Hospital of Austin HeartWare International Hellman & Friedman HepaLife Hi-Tech Pharmacal Hisamitsu Pharmaceutical Hologic Home Diagnostics Hongshan Pharmaceuticals Hospira Human Genome Sciences Huxley Pharmaceuticals Hyaluron Hypermarcas I-Flow Icagen Idenix Pharmaceuticals Ignyta Illumina Image Sensing Systems ImaRX IMMCO Diagnostics Immucor ImmuMetrix Immune Pharmaceuticals Immunovative Therapies Impulse Monitoring INC Research Incline Therapeutics Indevus Pharmaceuticals Infinity Oil & Gas Inhibitex Innovus Pharmaceuticals Inovio Biomedical Insmed Inc Inspire Pharmaceuticals Intellipharmaceutics International Specialty Products InVentiv Health Inverness Medical Innovations InVivo InVivo Therapeutics ISTA Pharmaceuticals Javelin Pharmaceuticals Jazz Pharmaceuticals Jefferies & Company Johnson & Johnson Juniper Investment Company Kendle International Kimberly-Clark Kinetic Concepts King Pharmaceuticals Kinray La Jolla Pharmaceutical Laboratory Corporation of America Lantis Laser LEAD Therapeutics LecTec LEO Pharma Lexicon Pharmaceuticals LFB Biomedicaments Life Technologies Ligand Pharmaceuticals Link Resources Lipocine LMA International Luminex MAKO Surgical Mallinckrodt Pharmaceuticals Manhattan Pharmaceuticals Manhattan Scientifics Mantecorp
Recommended publications
  • Appendix a 2016 Financial Report Financial Review Pfizer Inc

    Appendix a 2016 Financial Report Financial Review Pfizer Inc

    Appendix A 2016 Financial Report Financial Review Pfizer Inc. and Subsidiary Companies GLOSSARY OF DEFINED TERMS Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2016 Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this 2016 Financial Report, most of which are explained or defined below: 2016 Financial Report This Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 2016 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2016 AAV Adeno-Associated Virus ABO Accumulated postretirement benefit obligation ACA (Also referred to as U.S. U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Healthcare Legislation) Act. ACIP Advisory Committee on Immunization Practices ALK anaplastic lymphoma kinase Allergan Allergan plc Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us AM-Pharma AM-Pharma B.V. Anacor Anacor Pharmaceuticals, Inc. Astellas Astellas Pharma U.S. Inc. ASU Accounting Standards Update ATM-AVI aztreonam-avibactam Bamboo Bamboo Therapeutics, Inc. Baxter Baxter International Inc. BMS Bristol-Myers Squibb Company CDC U.S. Centers for Disease Control and Prevention Cellectis Cellectis SA Celltrion Celltrion Inc. and Celltrion Healthcare,
  • [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical

    [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical

    This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
  • Transcept Pharmaceuticals, Inc

    Transcept Pharmaceuticals, Inc

    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
  • Curriculum Vitae: Daniel J

    Curriculum Vitae: Daniel J

    CURRICULUM VITAE: DANIEL J. WALLACE, M.D., F.A.C.P., M.A.C.R. Up to date as of January 1, 2019 Personal: Address: 8750 Wilshire Blvd, Suite 350 Beverly Hills, CA 90211 Phone: (310) 652-0010 FAX: (310) 360-6219 E mail: [email protected] Education: University of Southern California, 2/67-6/70, BA Medicine, 1971. University of Southern California, 9/70-6/74, M.D, 1974. Postgraduate Training: 7/74-6/75 Medical Intern, Rhode Island (Brown University) Hospital, Providence, RI. 7/75-6/77 Medical Resident, Cedars-Sinai Medical Center, Los Angeles, CA. 7/77-6/79 Rheumatology Fellow, UCLA School of Medicine, Los Angeles, CA. Medical Boards and Licensure: Diplomate, National Board of Medical Examiners, 1975. Board Certified, American Board of Internal Medicine, 1978. Board Certified, Rheumatology subspecialty, 1982. California License: #G-30533. Present Appointments: Medical Director, Wallace Rheumatic Study Center Attune Health Affiliate, Beverly Hills, CA 90211 Attending Physician, Cedars-Sinai Medical Center, Los Angeles, 1979- Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, 1995- Professor of Medicine, Cedars-Sinai Medical Center, 2012- Expert Reviewer, Medical Board of California, 2007- Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, 2010- Board of Governors, Cedars-Sinai Medical Center, 2016- Member, Medical Policy Committee, United Rheumatology, 2017- Honorary Appointments: Fellow, American College of Physicians (FACP) Fellow, American College of Rheumatology (FACR)
  • RESI Boston Program Guide 09-26-2017 Digital

    RESI Boston Program Guide 09-26-2017 Digital

    SEPTEMBER 26 , 2017 BOSTON, MA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESIBOS17 | RESIConference.com | Boston Marriott Copley Place FLOOR PLAN Therapeutics Track 2 Investor Track 3 & track4 Track 1 Device, Panels Workshops & Diagnostic & HCIT Asia Investor Panels Panels Ad-Hoc Meeting Area Breakfast & Lunch DINING 29 25 30 26 31 27 32 28 33 29 34 30 35 Breakfast / LunchBreakfast BUFFETS 37 28 24 27 23 26 22 25 21 24 20 23 19 22 exhibit hall 40 15 13 16 14 17 15 18 16 19 17 20 18 21 39 INNOVATION 14 12 13 11 12 10 11 9 10 8 9 7 8 EXHIBITORS CHALLENGE 36 38 FINALISTS 1 1 2 2 3 3 4 4 5 5 6 6 7 Partnering Check-in PARTNERING Forum Lunch BUFFETS Breakfast / Breakfast RESTROOM cocktail reception REGISTRATION content Welcome to RESI - - - - - - - - - - - - - - - 2 RESI Agenda - - - - - - - - - - - - - - - - - - 3 BOSTON RESI Innovation Challenge - - - - - - - 5 Exhibiting Companies - - - - - - - - - - 12 Track 1: Therapeutics Investor Panels - - - - - - - - - - - - - - - 19 Track 2: Device, Diagnostic, & HCIT Investor Panels - - - - 29 Track 3: Entrepreneur Workshops - - - - - - - - - - - - - - - - - - 38 Track 4: Asia-North America Workshop & Panels - - - - - - 41 Track 5: Partnering Forum - - - - - - - - - - - - - - - - - - - - - - - - 45 Sponsors & Media Partners - - - - - - - - - - - - - - - - - - - - - - - 46 1 welcome to resi On behalf of Life Science Nation (LSN) and our title sponsors WuXi AppTec and Johnson & Johnson Innovation JLABS, I would like to thank you for joining us at RESI Boston. LSN is very happy to welcome you all to Boston, the city where it all began, for our 14th RESI event.
  • Manufacturers and Wholesalers Street

    Manufacturers and Wholesalers Street

    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
  • OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

    OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

    OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration July 21, 2009 9:24 PM ET MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007. The alliance is anchored around developing molecular targeted therapies to target the underlying mechanisms of epithelial-mesenchymal transition (EMT) in cancer and to develop proprietary datasets of associated patient selection biomarkers to support OSI’s targeted medicine pipeline. EMT is a process of emerging significance in tumor development and disease progression and the focal point of OSI’s proprietary oncology research efforts. The companies are expanding their efforts to validate cancer targets and to deploy key elements of AVEO’s proprietary translational research platform in support of OSI’s clinical development programs. Under the terms of the expanded discovery and research agreement, OSI will pay AVEO a total of $20 million at closing, $5 million of which is an upfront cash payment and $15 million of which is the purchase of additional equity in AVEO. OSI will also provide AVEO research funding over the next two years to support the collaboration, and the potential to achieve additional royalties and milestones. In return, OSI will immediately receive rights beyond the original collaboration including rights to additional EMT targets (including up to 4 antibody targets) and increased access to AVEO technology (i.e. tumor models, archives and biomarkers). OSI is also acquiring non-exclusive access to AVEO’s proprietary bioinformatics platform.
  • PULSE: Speaker Biographies March 2019

    PULSE: Speaker Biographies March 2019

    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
  • IPR2016-01284 Patent 6,900,221 B1 ______

    IPR2016-01284 Patent 6,900,221 B1 ______

    [email protected] Paper No. 49 571.272.7822 Filed: January 8, 2018 UNITED STATES PATENT AND TRADEMARK OFFICE ____________________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________________ APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS HOLDINGS INC., AND APOTEX HOLDINGS, INC., Petitioner, v. OSI PHARMACEUTICALS LLC, Patent Owner. ____________________ Case IPR2016-01284 Patent 6,900,221 B1 ____________ Before LORA M. GREEN, RAMA G. ELLURU, and ZHENYU YANG, Administrative Patent Judges. GREEN, Administrative Patent Judge. FINAL WRITTEN DECISION Determining That Claims 44‒46 and 53 Are Shown to Be Unpatentable 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73 IPR2016-01284 Patent 6,900,221 B1 I. INTRODUCTION Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc., (“Apotex” or “Petitioner”) filed a Petition requesting an inter partes review of claims 44–47 and 53 of U.S. Patent No. 6,900,221 B1 (Ex. 1001, “the ’221 patent”). Paper 3 (“Pet.”). OSI Pharmaceuticals LLC1 (“OSI” or “Patent Owner”) filed a Preliminary Response to the Petition.2 Paper 7 (“Prelim. Resp.”). We determined that the information presented in the Petition and the Preliminary Response demonstrated that there was a reasonable likelihood that Petitioner would prevail in challenging claims 44–47 and 53 as unpatentable under 35 U.S.C. § 103(a). Pursuant to 35 U.S.C. § 314, we instituted trial on January 9, 2017, as to all of the challenged claims of the ’221 patent. Paper 8 (“Institution Decision” or “Dec. Inst.”). On February 8, 2017, the parties filed a Joint Motion to Limit Petition Under 37 C.F.R.
  • Management Team

    Management Team

    Management Team Bruce C. Cozadd Executive Chairman Bruce Cozadd joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Mr. Cozadd served as a consultant to companies in the biopharmaceutical industry. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. Samuel R. Saks, MD Chief Executive Officer Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology. Robert M. Myers President Robert Myers joined Jazz Pharmaceuticals at its inception and was appointed as Jazz Pharmaceuticals’ President in March 2007.
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.